Loading clinical trials...
Loading clinical trials...
DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors
Conditions
Interventions
Biopsy Procedure
Biospecimen Collection
+9 more
Locations
1
United States
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, United States
Start Date
July 16, 2019
Primary Completion Date
June 1, 2026
Completion Date
June 1, 2026
Last Updated
April 13, 2026
NCT04879121
NCT04693377
NCT06500455
NCT06311214
NCT04550494
NCT04704661
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions